loading
Precedente Chiudi:
$0.309
Aprire:
$0.302
Volume 24 ore:
568.64K
Relative Volume:
0.24
Capitalizzazione di mercato:
$17.11M
Reddito:
$30.99M
Utile/perdita netta:
$-141.41M
Rapporto P/E:
-2.094
EPS:
-0.15
Flusso di cassa netto:
$-118.12M
1 W Prestazione:
-1.00%
1M Prestazione:
-83.21%
6M Prestazione:
-77.02%
1 anno Prestazione:
-94.86%
Intervallo 1D:
Value
$0.302
$0.3151
Intervallo di 1 settimana:
Value
$0.2912
$0.328
Portata 52W:
Value
$0.2603
$11.26

Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile

Name
Nome
Marinus Pharmaceuticals Inc
Name
Telefono
484-801-4670
Name
Indirizzo
5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA
Name
Dipendente
166
Name
Cinguettio
@MarinusPharma
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
MRNS's Discussions on Twitter

Confronta MRNS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
MRNS 0.312 17.11M 30.99M -141.41M -118.12M -0.15
VRTX 449.81 115.43B 10.63B -479.80M -1.35B 13.33
REGN 745.30 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 595.64 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.18 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.10 24.89B 3.30B -501.07M 1.03B 11.54

Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-01-20 Iniziato RBC Capital Mkts Outperform
2020-09-30 Iniziato Truist Buy
2020-07-01 Iniziato Cowen Outperform
2020-07-01 Reiterato H.C. Wainwright Buy
2020-04-09 Iniziato Craig Hallum Buy
2019-12-20 Iniziato Oppenheimer Outperform
2019-03-05 Ripresa Jefferies Buy
2019-02-27 Downgrade Mizuho Buy → Neutral
2019-02-06 Iniziato Leerink Partners Outperform
2018-07-02 Iniziato Cantor Fitzgerald Overweight
2018-03-20 Iniziato Mizuho Buy
2018-02-15 Iniziato H.C. Wainwright Buy
2017-12-14 Iniziato Laidlaw Buy
2016-08-10 Reiterato Jefferies Buy
2016-06-14 Downgrade RBC Capital Mkts Outperform → Sector Perform
2016-03-08 Reiterato Stifel Buy
2015-12-17 Iniziato RBC Capital Mkts Outperform
2015-11-17 Iniziato Jefferies Buy
2015-10-30 Reiterato Oppenheimer Outperform
2015-08-05 Reiterato Oppenheimer Outperform
Mostra tutto

Marinus Pharmaceuticals Inc Borsa (MRNS) Ultime notizie

pulisher
02:13 AM

Layoff Tracker: J&J, Merck Trimming Workforces in China - BioSpace

02:13 AM
pulisher
Nov 20, 2024

Marinus Pharmaceuticals Reports Q3 2024 Financial Results and Strategic Developments - MSN

Nov 20, 2024
pulisher
Nov 15, 2024

MRNS (Marinus Pharmaceuticals) Degree of Operating Leverage : 65.26 (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Marinus Pharmaceuticals Third Quarter 2024 Earnings: Revenues Disappoint - Simply Wall St

Nov 15, 2024
pulisher
Nov 15, 2024

US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results - Yahoo Finance

Nov 15, 2024
pulisher
Nov 14, 2024

Marinus Pharmaceuticals Lays Off 45% of Employees - BioSpace

Nov 14, 2024
pulisher
Nov 14, 2024

Marinus Pharmaceuticals Faces Financial Turmoil Amidst Class Action Lawsuit - TipRanks

Nov 14, 2024
pulisher
Nov 13, 2024

Marinus Pharmaceuticals Reports Q3 Growth in ZTALMY Revenue - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Marinus Pharmaceuticals' SWOT analysis: navigating challenges in rare epilepsy stock - Investing.com India

Nov 13, 2024
pulisher
Nov 13, 2024

Marinus Pharmaceuticals: Q3 Earnings Snapshot - Darien Times

Nov 13, 2024
pulisher
Nov 12, 2024

Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Marinus Pharmaceuticals Inc Reports Q3 2024 Revenue of $8.54M, G - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - The Bakersfield Californian

Nov 12, 2024
pulisher
Nov 01, 2024

Marinus Pharmaceuticals Faces Setback with Phase 3 TrustTSC Trial - MSN

Nov 01, 2024
pulisher
Oct 29, 2024

Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment - Investing.com Canada

Oct 29, 2024
pulisher
Oct 28, 2024

Greenlane Holdings to Distribute CURB’s Innovative Inhalation Device: A Game-Changer? - BP Journal

Oct 28, 2024
pulisher
Oct 28, 2024

Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment By Investing.com - Investing.com South Africa

Oct 28, 2024
pulisher
Oct 27, 2024

Marinus downgraded after setback to late-stage trial - MSN

Oct 27, 2024
pulisher
Oct 26, 2024

Marinus Pharmaceuticals Hosts Investor and Analyst Day - MSN

Oct 26, 2024
pulisher
Oct 26, 2024

TD Cowen Downgrades Marinus Pharmaceuticals (MRNS) - MSN

Oct 26, 2024
pulisher
Oct 26, 2024

Marinus tanks after late stage trial for treatment of seizures in TSC fails to meet main goal - MSN

Oct 26, 2024
pulisher
Oct 26, 2024

Marinus Pharmaceuticals (MRNS) Halts Ganaxolone Development for TSC After Phase 3 Trial Failure - BP Journal

Oct 26, 2024
pulisher
Oct 25, 2024

Marinus Pharmaceuticals Expands Intellectual Property Portfolio with New ZTALMY® Patent - MSN

Oct 25, 2024
pulisher
Oct 25, 2024

Marinus Pharmaceuticals price target lowered to $1 from $3 at RBC Capital - TipRanks

Oct 25, 2024
pulisher
Oct 25, 2024

Marinus stock downgraded after trial setback (MRNS:NASDAQ) - Seeking Alpha

Oct 25, 2024
pulisher
Oct 25, 2024

HC Wainwright Reiterates "Neutral" Rating for Marinus Pharmaceuticals (NASDAQ:MRNS) - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Marinus’ clinical trial of ganaxolone fails to meet primary endpoint - Yahoo! Voices

Oct 25, 2024
pulisher
Oct 25, 2024

Marinus Pharma Halts Development After Seizure Drug Fails Trial - Medical Dialogues

Oct 25, 2024
pulisher
Oct 25, 2024

JMP Securities Downgrades Marinus Pharmaceuticals (MRNS) - MSN

Oct 25, 2024
pulisher
Oct 25, 2024

Marinus halts ganaxolone development after trial setback - Investing.com India

Oct 25, 2024
pulisher
Oct 25, 2024

Jefferies cuts Marinus Pharma to hold, slashes target to $0.50 - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

Marinus Pharmaceuticals downgraded to Hold from Buy at Jefferies - TipRanks

Oct 24, 2024
pulisher
Oct 24, 2024

Jefferies cuts Marinus Pharma to hold, slashes target to $0.50 By Investing.com - Investing.com UK

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus halts ganaxolone development after trial setback By Investing.com - Investing.com Australia

Oct 24, 2024
pulisher
Oct 24, 2024

Truist cuts Marinus Pharma to hold, drops price target - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Truist cuts Marinus Pharma to hold, drops price target By Investing.com - Investing.com UK

Oct 24, 2024
pulisher
Oct 24, 2024

Baird cuts Marinus Pharma target to $0.50 on failed study - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options - AOL

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus Pharmaceuticals price target lowered to 50c from $2 at Baird - TipRanks

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus Pharmaceuticals downgraded to Market Perform at JMP Securities - TipRanks

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus to trim workforce, weigh 'strategic alternatives' after another Ztalmy trial miss sends shares tumbling - FiercePharma

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus Pharma stock plunges to 52-week low of $0.52 - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus hits record low after discontinuing development of rare disease drug - XM

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus Pharma stock plunges to 52-week low of $0.52 By Investing.com - Investing.com Canada

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus Pharmaceutical Shares Plumb New Depths After Study Failure - MarketWatch

Oct 24, 2024
pulisher
Oct 24, 2024

Marinus Therapeutics plans layoffs, explores strategic alternatives as shares sink - The Business Journals

Oct 24, 2024

Marinus Pharmaceuticals Inc Azioni (MRNS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Marinus Pharmaceuticals Inc Azioni (MRNS) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Shafer Christina
CHIEF COMMERCIAL OFFICER
Aug 05 '24
Sale
1.14
3,820
4,355
67,406
MANNING MARTHA E
SVP, GEN. COUNSEL & CORP. SEC.
Aug 05 '24
Sale
1.13
3,621
4,092
60,263
Hulihan Joseph
CHIEF MEDICAL OFFICER
Aug 05 '24
Sale
1.13
4,828
5,456
72,725
Braunstein Scott
CHAIRMAN AND CEO
Aug 05 '24
Sale
1.13
12,145
13,724
298,667
Braunstein Scott
CHAIRMAN AND CEO
Mar 27 '24
Option Exercise
4.28
50,000
214,000
273,512
Shafer Christina
CHIEF COMMERCIAL OFFICER
Feb 20 '24
Sale
9.56
2,153
20,583
60,308
MANNING MARTHA E
SVP, GEN. COUNSEL & CORP. SEC.
Feb 20 '24
Sale
9.57
1,894
18,126
52,966
Hulihan Joseph
CHIEF MEDICAL OFFICER
Feb 16 '24
Sale
9.98
2,814
28,084
66,635
Pfanstiel Steven
CFO AND COO
Feb 16 '24
Sale
9.97
3,092
30,827
71,697
Braunstein Scott
CHAIRMAN AND CEO
Feb 16 '24
Sale
9.94
11,850
117,789
223,512
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):